The Bulletin
Men's Weekly


.

CARsgen Submitted Responses to FDA Observations

  • Written by PR Newswire
CARsgen Submitted Responses to FDA Observations

SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive Actions (CAPAs) plan have been submitted to the...